Aug 21, 2019
The anti-GBM activity of the compounds were determined using cell migration and proliferation assays in U87 MG, DBTRG MG and EA.hy926 cells.
Glioblastoma (GBM) is a highly angiogenic malignant primary brain tumor with very poor patient survival rates. Here, we present Rosmarinic acid and its new salt and base derivatives that show potential anti-glioblastoma (anti-GBM) activity via disruption of IL17A-mediated downstream angiogenesis pathway. These new compounds were rationally designed, synthesized and the oral CNS physicochemical properties were determined.
